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Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is
seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most
tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be
targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases
from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive
systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is
summarized.
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Dermatofibrosarcoma Protuberans (DFSP) is a rare fibro-
histiocytic tumor of the skin or subcutaneous tissue that is
often locally infiltrative but rarely metastatic [1,2]. Cytoge-
netically, DFSP is characterized by a pathognomonic trans-
location t(17;22) (22;q13) with fusion of the COL1A1 gene
on chromosome 17 with the PDGFB gene on chromosome
22 [3]. This event results in constitutive expression of
ligand PDGFB creating an autocrine stimulatory loop
that drives cell proliferation and fibrosis. Clinically, it
commonly presents in younger adults growing slowly
over many years [2,4]. Microsatellite instability and p53
mutations are involved in tumor progression to the
fibrosarcomatous variant (DFSP-FS) [5]. Although the
major recurrence risk for DFSP is local relapse, DFSP-FS
subtype is associated with an aggressive clinical course,
more likely to develop distant metastases [6,7]. Several
case reports in the literature have demonstrated that DFSP
can metastasize to the lungs [8-10], as well as, pancreatic
or retroperitoneal spaces similar to the current case
[11-13]. The optimal treatment of primary and meta-
static DFSP is complete surgical resection with negative* Correspondence: jfosterm@unmc.edu
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unless otherwise stated.margins [14]. Over 90% of DFSPs, demonstrate a constitu-
tive activation of platelet-derived growth factor receptor,
making inhibition with a promiscuous tyrosine kinase
inhibitor (TKI), Imatinib a good option for unresect-
able, recurrent, or metastatic disease [15]. There have
been several reports of neoadjuvant Imatinib for locally
advanced primary tumors and adjuvant Imatinib for
resected margin positive primary disease and metastatic
disease [16-20]. There have been no published reports
of neoadjuvant Imatinib for unresectable metastatic DFSP
to the pancreas successfully treated and subsequently
resected. Here, we present the first reported case of
unresectable metastatic DFSP to the pancreas, success-
fully resected following neoadjuvant Imatinib. Addition-
ally, we conducted a systematic review of the literature
for pancreatic metastases of DFSP and use of Imatinib
in DFSP.Case presentation
A 31 year old African American male was diagnosed
with DFSP of the skin and soft tissue of the anterior left
chest wall and shoulder in 2005 and underwent local
excision at an outside facility in December, 2005. Grossly,
the excised specimen consisted of a 22.0 × 18.0 × 9.5 cm
portion of skin & subcutaneous tissue that contained a
multinodular and glistening dermal & subcutaneous mass.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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atypical spindled cells arranged in a storiform pattern that
invaded the dermis and subcutaneous tissue (Figure 1A).
Large parts of this tumor showed areas histologically rem-
iniscent of fibrosarcoma (at least 75% of the tumor),Figure 1 Histology of Primary tumor. A) The left chest wall mass
excised in 2005 showed an invasive spindle cell neoplasm with
B) areas of high grade, fibrosarcomatous transformation with
Herringbone architecture. C) The tumor showed CD34 expression
and this, along with the fibrosarcomatous areas and high mitotic
rate, were consistent with a dermatofibrosarcoma protuberans with
fibrosarcomatous transformation (DFSP-FS).characterized by spindled mesenchymal cells with high
grade cytologic atypia arranged in broad fascicles form-
ing a “Herringbone” pattern (Figure 1B), with more than
10 mitotic figures per high powered field. This neo-
plasm showed expression of CD34 by immunohisto-
chemistry (Figure 1C), but was negative for Desmin,
S100, Pan-cytokeratin, BCL-2, and CD117 expression.
The deep margin of resection was focally positive for
the neoplasm. A diagnosis of dermatofibrosarcoma protu-
berans with fibrosarcomatous transformation (DFSP-FS)
was rendered.
The patient received no other therapy at that time
and did well until October 2007, when he presented to
the emergency department with severe anemia and a
hemoglobin of 4 g/dL. Surgical Oncology was consulted
after an abdominal CT scan revealed a heterogeneous
mass in the left upper quadrant involving the pancreas,
spleen, adrenal, left lobe of liver, and stomach measur-
ing 17 × 18 × 23 cm (Figure 2A). A core biopsy of this
retroperitoneal mass was obtained that showed spindle
shaped mesenchymal cells with high grade cytologic atypia
(Figure 2B) essentially identical to the fibrosarcomatous
areas that were seen in the 2005 chest wall DFSP-FS.
These malignant cells showed an identical immunopheno-
type as the original chest wall tumor (see above). A dual
fusion DNA FISH probe set for the COL1A1 (17q21) and
PDGFB (22q13) genes was positive for a COL1A1-PDGFB
translocation (Figure 2C), consistent with DFSP-FS metas-
tasis to the retroperitoneum.
Radiographically, this retroperitoneal tumor was unre-
sectable and the patient was started on Imatinib therapy
400 mg BID. The patient tolerated this dose without any
reported side effects and after 18 months of Imatinib
therapy, the tumor exhibited a dramatic response with
a 70% size reduction and radiographically appeared to
be amenable to margin negative (R0) surgical resection
(Figure 3). A left upper quadrant exenteration (en-bloc
resection including a subtotal distal pancreatectomy,
splenectomy, left adrenalectomy, and subtotal gastrec-
tomy) was performed with negative margins on September
1, 2009 (Figure 4A-C). Post-Imatinib, this resected tumor
showed dramatically altered histology, revealing primar-
ily hyalinized and myxoid fibrous differentiated stroma
(Figure 5A) with focal atypical spindle cells (Figure 5B-C)
that revealed a COL1A1-PDGFB fusion by interphase
FISH analysis, consistent with a dramatic gross and histo-
logic response of the metastatic DFSP-FS to the Imatinib.
The lymph nodes were negative for tumor.
The patient resumed adjuvant Imatinib for 6 months
and remained free of disease for 14 months, off ther-
apy. His imaging at 14 months revealed para-aortic
nodal disease without evidence of local recurrence
that responded to reinstitution of Imatinib at the same
dose. The patient is now five years out from the initial
Coronal view




Figure 2 Radiographs of metastatic disease at diagnosis. A) CT scan demonstrating a large unresectable tumor involving all organs in the
left upper abdomen. B) Biopsy of this mass showed malignant high grade spindled cells, C) a COL1A1-PDGFB translocation by dual fusion FISH
probe set (yellow signals indicate the fusion signal), consistent with metastatic dermatofibrosarcoma protuberans with fibrosarcomatous
transformation (DFSP-FS).
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sion on Imatinib.
Systematic review: Pancreatic metastasis of
Dermatofibrosarcoma Protuberans
Methodology
A Medline search was performed using the key words
(a) “Pancreatic metastasis” AND “Dermatofibrosarcoma
Protuberans” (b) “Pancreas” AND “Dermatofibrosarcoma
Protuberans”. Similarly, an Embase search was performed
using the key words (a) “Pancreatic metastasis” AND
“Dermatofibrosarcoma Protuberans”. Medline and Embase
search using strategy (a) revealed 2 articles [13,21]. Search
strategy (b) identified 3 articles [11,13,22]. Backwardsearch was performed using the references from full
texts of these 4 articles and no additional articles were
found.
Results
We identified 4 articles reporting pancreatic metastases
from DFSP [11,13,21,22]. A summary of these articles is
provided in Additional file 1. Two of these patients were
found to have pancreatic metastases during follow up
and this appeared to be the only site of metastases [13,21].
In another patient reported by Winter et al., diagnosis was
not clear preoperatively [11]. Interestingly, all three of
these patients had aggressive disease with fibrosarcoma-
tous variant of DFSP, high mitotic counts, relatively short
Figure 3 CT scan illustrating post imatinib decrease in size of the tumor now amenable to surgical resection.
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prior to development of metastatic disease. In the report
by Onoda et al. a patient had multiple local recurrences
with relatively more aggressive features at each recurrence
and finally died of brain metastases. Patient was found to
have pancreatic and other systemic metastases at autopsy.
No studies described the use of Imatinib as a neoadjuvant
strategy to treat the pancreatic metastases.
Systematic review: use of Imatinib in
Dermatofibrosarcoma Protuberans
Methodology
Figure 6 describes the search strategy in detail. A Medline
search was performed using key words “Imatinib” AND
“Dermatofibrosarcoma Protuberans” which resulted in 98
articles. A title and abstract review (wherever available) of
all articles was performed. After exclusion of preclinical
studies (studies on cell lines) we were able to identify 48
articles which mentioned DFSP and either implied or
reported the use of Imatinib in patients. Full texts of
these 45 articles were reviewed. Information was gath-
ered from abstracts only, for 3 studies in non-English
languages. Backward search was also performed using
the references of these 45 articles and full texts of 12
randomly selected review articles. Twelve studies were
excluded (exclusion criteria mentioned in Figure 6).
Briefly, exclusion criteria include a) studies which did
not use Imatinib b) duplicate studies c) studies which
discussed molecular characteristics only d) critiques ofother case reports e) described patients whose primary
diagnosis was not DFSP. A total of 36 articles were
included in the systematic review [16,18-20,23-54].
Response to Imatinib was defined as complete clinical or
pathologic response, partial response or stable disease.
After completing the Medline search, an Embase
search was also performed using key words “Imatinib”
AND “Dermatofibrosarcoma Protuberans” which revealed
348 items including 152 review articles. After exclusion of
studies already identified using Medline search, we were
able to identify an additional 5 case reports [55-59] and 6
case series [60-65] (5 in abstract form [60,61,63-65]).
There was one more case report in non-English language,
describing neoadjuvant Imatinib for DFSP of the face, for
which no abstract was available [66].
Results
We identified 23 case reports [19,20,23-25,27,29-32,35,38,
39,41,42,50-52], [55-59], 15 case series [16,26,33,34,36,
37,45,47,53,60-65], 6 phase II studies [18,40,46,48,49]
and 4 pediatric studies [28,43,44,54] where Imatinib was
used for the treatment of patients with DFSP. These
studies include a total of 199 patients. Additional files 2,
3, 4 and 5 provide a summary of these studies including
case reports (Additional file 2), case series (Additional
file 3), phase II studies (Additional file 4) and pediatric
reports/series (Additional file 5). A phase II study of
malignancies associated with Imatinib sensitive tyrosine
kinases, by Heinrich et al. was excluded. A subset of
Figure 4 Gross R0 tumor resection specimen: subtotal distal pancreatectomy, subtotal gastrectomy, splenectomy, adrenalectomy.
A) Anterior view B) Posterior view C) Cross sectional view.
Dhir et al. Clinical Sarcoma Research 2014, 4:8 Page 5 of 10
http://www.clinicalsarcomaresearch.com/content/4/1/8
Figure 5 Histology post-Imatinib Resected retroperitoneal tumor showed a hyalinized hypocellular mass. A) Splenic tissue is demonstrated
on the left in the current section. B & C) Focally, the tumor demonstrated residual atypical spindle cells that revealed a COL1A1-PDGFB fusion by
interphase FISH (not shown), consistent with a dramatic histologic response of metastatic DFSP-FS to Imatinib.
Dhir et al. Clinical Sarcoma Research 2014, 4:8 Page 6 of 10
http://www.clinicalsarcomaresearch.com/content/4/1/8
AB
Figure 6 Search strategy flow diagrams. A & B Diagrams depicting the search strategy for systematic review of the use of Imatinib in patients
with Dermatofibrosarcoma Protuberans.
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and reported separately by McArthur et al. [40,67].
All except one case report described some response to
Imatinib [38]. Since the response assessment criteria var-
ied in many case series and to minimize bias, only phase
II studies were used for calculation of percentage response
to Imatinib. Overall combined response rate (Complete,
partial or stable disease) was 65% (48/74 patients) in phase
II studies. Common indications for use of Imatinib in
the selected studies included locally advanced primary,
primary tumor in a cosmetically sensitive location,
locally recurrent tumors, positive margins or metastatic
disease. Commonly used dosages include 400 mg/day,
400 mg twice daily or 800 mg/day. Some studies utilized
a dose escalation strategy where patients were started
on 400 mg/day and dose was gradually increased to
600 mg/day and then 800 mg/day based on tolerance
and side effects. Others utilized a higher dose of 400 mg
twice daily or 800 mg/day and decreased the dose depend-
ing on the side effects. Duration of adjuvant strategy
varied from 2 months to 2 years whereas neoadjuvant
treatment was guided by response of the tumor to the
therapy.
Discussion
To our knowledge, this is the first case report where an
unresectable pancreatic metastasis was treated in a neoad-
juvant fashion with Imatinib and an R0 resection was suc-
cessfully performed. Consistent with findings observed in
neoadjuvant therapy for primary cutaneous disease, when
a clinical and radiographic reduction in tumor size is
observed, it corresponds with the histologic findings of
markedly decreased cellularity as evidenced by fewer
CD34+ cells, along with significant hyalinization of
dermal collagen as seen in our case (Figure 5A-C). In
the current case, neoadjuvant Imatinib resolved the pre-
senting symptoms (GI bleeding, anemia, and pain) and
enabled R0 resection of an unresectable metastasis. The
dose of 400 mg BID was selected based on the only pub-
lished phase II study, B2225 at that time in 2007 [40].
This study reported a 100% response rate in eight lo-
cally advanced t (17;22) positive DFPS tumors with four
patients (50%) exhibiting complete responses. Addition-
ally McArthur et al. reported 7/8 (88%) patients toler-
ated the therapy with only one patient requiring dose
reduction to 600 mg. Since B2225 three additional
phase II trials (Additional file 4) have been conducted
evaluating 400 mg, 600 mg and 800 mg doses which have
reported similar efficacy and tolerance profiles [46,49].
In this case 400 mg BID Imatinib followed by resec-
tion facilitated excellent local control evident now 5 years
post metastatectomy, 10-years from primary cutaneous
diagnosis without resection bed recurrence. Although, the
patient did develop distant, para-aortic nodal metastasis14 months post-resection, metastatic disease remained
Imatinib responsive and demonstrated radiographic reso-
lution with therapy. Importantly the patient did not report
any significant gastrointestinal or other side effects during
neoadjuvant therapy or subsequent therapy for nodal
recurrence.
Conclusions
In conclusion, given the intrinsic biological sensitivity of
COL1A1/PDGFB positive DFSP to Imatinib, neoadjuvant
therapy with this medication may not only be an import-
ant tool in managing locally advanced and recurrent
cutaneous disease but equally valuable in unresectable or
marginally resectable metastatic DFSP; facilitating margin
negative resection, improving local control, and extending
disease free and overall survival. The response observed
following neoadjuvant Imatinib may also be useful as an
in vivo test of tumor’s responsiveness and may be useful
in determine the best post-operative adjuvant therapy.
Neoadjuvant and adjuvant Imatinib is well established in
Gastrointestinal Stromal Tumors (GIST), unlike in DFSP.
The results from the closed clinical trial NCT00243191/
SARC004 will provide insight into the value of short
course therapy in cutaneous disease but additional trials
are needed to address the value in the setting of metastatic
DFSP. This report highlights the value of neoadjuvant
Imatinib in facilitating surgical resection and the contin-
ued response of distant disease sites in a patient now over
5-years with metastatic DFSP.
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